Mayo Clinic researchers identify proteins linked to immunotherapy resistance in metastatic CRC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In findings published in Clinical Cancer Research, a research team at Mayo Clinic identified specific proteins—fibronectin and smooth muscle actin—within colorectal cancer tissues that are associated with resistance to immunotherapy treatment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Greg Sawyer, chair of the bioengineering department at Moffitt Cancer Center, has been awarded the 2023 Tribology Gold Medal by the International Tribology Council. This prestigious award is the highest honor in the field and recognizes individuals who have made extraordinary lifetime contributions to the study of friction, wear, and lubrication.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login